HOME > TOP STORIES
TOP STORIES
-
BUSINESS J&J's Drug-Device Combo Offers Weeks-Long Local Therapy for Bladder Cancer: Exec
May 8, 2026
-
REGULATORY Panel Backs Proposal to Allow Antibody Drugs Like Beyfortus in NIP
May 1, 2026
-
BUSINESS Gilead Files Bictegravir Plus Lenacapavir HIV Pill in Japan
April 30, 2026
-
REGULATORY MOF Pushes for Full-Scale FY2027 Off-Year Drug Price Revision Ahead of “Spring” Proposal
April 28, 2026
-
REGULATORY Japan Panel Backs Boehringer’s IPF Drug, Moderna COVID Vaccine
April 28, 2026
-
BUSINESS Astellas Taps Sanofi Japan Chief Iwaya as Strategy Officer
April 28, 2026
-
REGULATORY Zepbound in Line for OSA Approval after Key Panel Nod
April 27, 2026
-
BUSINESS Pharma Earnings Season Kicks Off; Off-Year Impact, Overseas Trends in Focus
April 24, 2026
-
BUSINESS Genmab Targets 2027 US Debut for 2 Cancer Drugs, CEO Eyes Blockbuster Potential
April 23, 2026
-
BUSINESS Bayer Eyes 2026 Launch for Sevabertinib under “3-Plus-3” Strategy in Japan
April 23, 2026
-
REGULATORY Extra Charges Likely for OTC-Like Drugs to Treat Seasonal Conditions: Minister
April 22, 2026
-
BUSINESS Jazz, Nippon Zoki Ink Deal to Bring Cannabis-Derived Epilepsy Drug to Japan
April 22, 2026
-
BUSINESS Novartis Japan Chief Urges Pro-Innovation Policies to Sustain Investments
April 21, 2026
-
ORGANIZATION PhRMA Warns Japan Launches Could Erode Global Revenues amid US MFN Policy
April 20, 2026
-
BUSINESS Sobi Japan Shoots for 8 to 9-Fold Growth by 2030 on Five Approvals
April 17, 2026
-
REGULATORY Unpacking “MFN”: Japan Listed as Reference Country in US Pricing Models
April 16, 2026
-
BUSINESS Sanofi Japan Sales Rise 4.5% in 2025 as Dupixent Widens Label
April 15, 2026
-
REGULATORY Japan Panel to Review Ferring Gene Therapy, Fujifilm Cell Product on April 20
April 14, 2026
-
BUSINESS AstraZeneca Lifts Japan Approval Target to 50-Plus by 2030 as Pipeline Advances
April 13, 2026
-
BUSINESS MSD Japan Eyes Up to 8 Approvals, 8-Plus Filings under New Chief
April 10, 2026
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
